Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 8/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 2/20 | 0.39 |
| ▸ | XIAP | P98170 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26675357 | 1.00 | GBA1 (0.42) | GBA1ENPP3ALPLXIAPHTT | |
| SCHEMBL26675406 | 0.87 | HSD17B10 (0.45) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL29767954 | 0.87 | HSD17B10 (0.45) | HTTMAPTSMN1; SMN2TP53PKM | |
| SCHEMBL26675388 | 0.86 | GBA1 (0.49) | GBA1ENPP3ALPLXIAPHTT | |
| SCHEMBL29767951 | 0.86 | GBA1 (0.49) | GBA1ENPP3ALPLXIAPHTT | |
| SCHEMBL29768164 | 0.79 | ENPP3 (0.40) | GBA1ENPP3ALPLXIAPHTT | |
| SCHEMBL26675446 | 0.79 | ENPP3 (0.40) | GBA1ENPP3ALPLXIAPHTT | |
| SCHEMBL29767974 | 0.78 | ENPP3 (0.41) | ENPP3ALPLXIAPHTTMAPT | |
| SCHEMBL26675306 | 0.78 | ENPP3 (0.41) | ENPP3ALPLXIAPHTTMAPT | |
| SCHEMBL29767972 | 0.77 | ENPP3 (0.43) | ENPP3ALPLXIAPHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116867782-A | Pyrazole amide derivative | 豪夫迈·罗氏有限公司 | 2023-10-10 | — | — | CN | claimed |
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| CN-116867782-A | Pyrazole amide derivative | 豪夫迈·罗氏有限公司 | 2023-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | P2RY1, P2RX1, P2RX5 | GBA1 510/4885ENPP3 1560/4885ALPL 3520/4885 |
| US-12630549-B2 | Pyrazoleamide derivatives | CYP11B2, CYP11B1, ADRA1B | GBA1 2014/4885ENPP3 2958/4885ALPL 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.